p217 Tau Luminescence Immunoassay
- Regulatory Status
- RUO
- Incubation time
- 1 x 3h
- Kit size
- 12 x 8
- Specimen / Volumes
- 50 µL plasma, serum, diluted eluate
- Standard range
- 1 - 100 pg/mL
- Substrate / isotope
- Luminol
Measure p217 Tau together with BD-Tau out of one BD-Tau eluate from blood and get the whole picture
The p217 Tau LUM is a sensitive research tool that together with an upfront BD-Tau immunoprecipitation allows for the measurement of p217 BD-Tau in blood samples.
the Human p217 Tau Luminescence Immunoassay is an enzyme immunoassay intended for the quantitative determination of p217 Tau protein from peripheral cell-free body fluids, such as blood plasma or serum, after enrichment of BD-Tau using the BD-Tau Neuro IP Kit (30290912).
Summary
The Tau protein is a microtubule-stabilizing protein being part of the axons of nerve cells in the central nervous system (CNS). Measuring total Tau in CSF reflects axonal destruction and has found its way into diagnostic criteria guidelines¹, but measuring total Tau in blood does not correlate with its corresponding CSF value. As 80% of Tau in blood originates from peripheral tissue, being able to selectively measure the brain-derived fraction will enhance specificity and accessibility of Tau as an AD biomarker.
p217 Tau has been shown to correlate with the Amyloid-beta pathology in Alzheimer's disease patients and can discriminate between so-called amyloid-beta-positive and amyloid-beta-negative patients (determined by CSF amyloid-beta measurement)
.Distributed by TECAN, IBL international
- Jack, C. R., Jr, Andrews, S. J., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., Molinuevo, J. L., Okonkwo, O. C., Pani, L., Rafii, M. S., Scheltens, P., Siemers, E., Snyder, H. M., Sperling, R., Teunissen, C. E., & Carrillo, M. C. (2024). Revised criteria for the diagnosis and staging of Alzheimer's disease.Nature medicine,30(8), 2121–2124. https://doi.org/10.1038/s41591-024-02988-7
- Marotta, C., Gonzalez-Ortiz, F., Turton, M., Zetterberg, H., Harrison, P., Hovens, C. M., Sinclair, B., O'Brien, T. J., Blennow, K., & Vivash, L. (2025). Brain-derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia. Alzheimer's & dementia (Amsterdam, Netherlands),17(2), e70123. https://doi.org/10.1002/dad2.70123
- Gonzalez-Ortiz, F., Kirsebom, B. E., Contador, J., Tanley, J. E., Selnes, P., Gísladóttir, B., Pålhaugen, L., Suhr Hemminghyth, M., Jarholm, J., Skogseth, R., Bråthen, G., Grøndtvedt, G., Bjørnerud, A., Tecelao, S., Waterloo, K., Aarsland, D., Fernández-Lebrero, A., García-Escobar, G., Navalpotro-Gómez, I., Turton, M., … Blennow, K. (2024). Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease. Nature communications, 15(1), 2908. https://doi.org/10.1038/s41467-024-47286-5
- Morgado, B., Klafki, H. W., Bauer, C., Waniek, K., Esselmann, H., Wirths, O., Hansen, N., Lachmann, I., Osterloh, D., Schuchhardt, J., & Wiltfang, J. (2025). Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer's disease.European archives of psychiatry and clinical neuroscience,275(8), 2215–2227. https://doi.org/10.1007/s00406-023-01751-2
- Gonzalez-Ortiz, F., Turton, M., Kac, P. R., Smirnov, D., Premi, E., Ghidoni, R., Benussi, L., Cantoni, V., Saraceno, C., Rivolta, J., Ashton, N. J., Borroni, B., Galasko, D., Harrison, P., Zetterberg, H., Blennow, K., & Karikari, T. K. (2023). Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. Brain : a journal of neurology, 146(3), 1152–1165. https://doi.org/10.1093/brain/awac407
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.